Evidence map›Paper›PMID 40248872›Full record

Observational studyCirculation. Genomic and precision medicine2025

Diagnostic MicroRNA Signatures to Support Classification of Pulmonary Hypertension.

Niamh Errington, Li Zhou, Christopher J Rhodes, Yiu-Lian Fong, Lihan Zhou, Sokratis Kariotis, Eileen Harder, Aaron Waxman, Timothy Jatkoe, John Wharton and 9 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Circulation. Genomic and precision medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Niamh Errington *National Heart and Lung Institute, Imperial College London, United Kingdom (N.E., C.J.R., J.W., L.S.H., D.W., M.R.W., A.L.).ORCID 0000-0001-6768-7394
Li Zhou *MiRXES Lab, Singapore, Republic of Singapore (Li Zhou, Lihan Zhou, C.H.).ORCID 0000-0002-4622-9877
Christopher J RhodesNational Heart and Lung Institute, Imperial College London, United Kingdom (N.E., C.J.R., J.W., L.S.H., D.W., M.R.W., A.L.).ORCID 0000-0002-4962-3204
Yiu-Lian FongJanssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ (Y.-L.F., T.J.).ORCID 0009-0003-8730-9077
Lihan ZhouMiRXES Lab, Singapore, Republic of Singapore (Li Zhou, Lihan Zhou, C.H.).ORCID 0000-0002-1096-2604
Sokratis KariotisBioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore (S.K., D.W.).
Eileen HarderBrigham and Women's Hospital and Harvard Medical School, Boston, MA (E.H., A.W.).
Aaron WaxmanBrigham and Women's Hospital and Harvard Medical School, Boston, MA (E.H., A.W.).ORCID 0000-0001-7797-0361
Timothy JatkoeJanssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ (Y.-L.F., T.J.).
John WhartonNational Heart and Lung Institute, Imperial College London, United Kingdom (N.E., C.J.R., J.W., L.S.H., D.W., M.R.W., A.L.).ORCID 0000-0001-8110-2575
A A Roger ThompsonDivision of Clinical Medicine, The University of Sheffield, United Kingdom (A.A.R.T., R.C., D.G.K.).ORCID 0000-0002-0717-4551
Robin A CondliffeDivision of Clinical Medicine, The University of Sheffield, United Kingdom (A.A.R.T., R.C., D.G.K.).
David G KielyDivision of Clinical Medicine, The University of Sheffield, United Kingdom (A.A.R.T., R.C., D.G.K.).ORCID 0000-0003-0184-6502
Luke S HowardNational Heart and Lung Institute, Imperial College London, United Kingdom (N.E., C.J.R., J.W., L.S.H., D.W., M.R.W., A.L.).ORCID 0000-0003-2822-210X
Mark ToshnerPapworth NHS Foundation, Cambridge, United Kingdom (M.T.).ORCID 0000-0002-3969-6143
Cheng HeMiRXES Lab, Singapore, Republic of Singapore (Li Zhou, Lihan Zhou, C.H.).ORCID 0000-0002-8102-8245
Dennis Wang *National Heart and Lung Institute, Imperial College London, United Kingdom (N.E., C.J.R., J.W., L.S.H., D.W., M.R.W., A.L.).ORCID 0000-0003-0068-1005
Martin R Wilkins *National Heart and Lung Institute, Imperial College London, United Kingdom (N.E., C.J.R., J.W., L.S.H., D.W., M.R.W., A.L.).ORCID 0000-0003-3926-1171
Allan Lawrie *National Heart and Lung Institute, Imperial College London, United Kingdom (N.E., C.J.R., J.W., L.S.H., D.W., M.R.W., A.L.).ORCID 0000-0003-4192-9505

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with pulmonary hypertension (PH) are classified based on disease pathogenesis and hemodynamic drivers. Classification informs treatment. The heart failure biomarker NT-proBNP (N-terminal pro-B-type natriuretic peptide) is used to help inform risk but is not specific to PH or sub-classification groups. There are currently no other biomarkers in clinical use to help guide diagnosis or risk.

methodsWe profiled a retrospective cohort of 1150 patients from 3 expert centers with PH and 334 non-PH symptomatic controls (disease controls) from the United Kingdom to measure circulating levels of 650 microRNAs (miRNAs) in serum. NT-proBNP (ELISA) and 326 well-detected miRNAs (polymerase chain reaction) were prioritized by feature selection using multiple machine learning models. From the selected miRNAs, generalized linear models were used to describe miRNA signatures to differentiate PH and pulmonary arterial hypertension from the disease controls, and pulmonary arterial hypertension, PH due to left heart disease, PH due to lung disease, and chronic thromboembolic pulmonary hypertension from other forms of PH. These signatures were validated on a UK test cohort and independently validated in the prospective CIPHER study (A Prospective, Multicenter, Noninterventional Study for the Identification of Biomarker Signatures for the Early Detection of Pulmonary Hypertension) comprising 349 patients with PH and 93 disease controls.

resultsNT-proBNP achieved a balanced accuracy of 0.74 and 0.75 at identifying PH and pulmonary arterial hypertension from disease controls with a threshold of 254 and 362 pg/mL, respectively but was unable to sub-categorize PH subgroups. In the UK cohort, miRNA signatures performed similarly to NT-proBNP in distinguishing PH (area under the curve of 0.7 versus 0.78), and pulmonary arterial hypertension (area under the curve of 0.73 versus 0.79) from disease controls. MicroRNA signatures outperformed NT-proBNP in distinguishing PH classification groups. External testing in the CIPHER cohort demonstrated that miRNA signatures, in conjunction with NT-proBNP, age, and sex, performed better than either NT-proBNP or miRNAs alone in sub-classifying PH.

conclusionsWe suggest a threshold for NT-proBNP to identify patients with a high probability of PH, and the subsequent use of circulating miRNA signatures to help differentiate PH subgroups.

Indexed as

Hypertension, PulmonaryMicroRNAsAdultAgedBiomarkersFemaleHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsRetrospective StudiesUnited KingdomBiomarkersMicroRNAsNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)biomarkersearly diagnosismachine learningmiRNApulmonary hypertension

Identifiers

PMID40248872
PMCPMC12173163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.